Vasculitis & polymyalgia rheumatica
The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 American College of Rheumatology (ACR)/EULAR Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Authors' conclusion
The concordance rate between the 2022 ACR/EULAR criteria for EGPA and the old criteria was 86.3%. The most important factor in the failure to reclassify patients as having EGPA was the exclusion of nonfixed pulmonary infiltrates in the 1990 ACR criteria for EGPA.
Study context
- Population
- Korean patients with previously diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) meeting the 1990 ACR criteria, 2007 European Medicines Agency algorithm and 2012 Chapel Hill Consensus Conference definitions
- Participants
- 51 patients
- Exposure
- 2022 ACR/EULAR criteria vs old criteria for EGPA
- Outcome
- Concordance rate between the 2022 ACR/EULAR criteria and the old criteria for EGPA
Methodological detailsreclassification study
- Reclassification study
Main finding
As reported in the abstract
Reclassified as EGPA by 2022 ACR/EULAR criteria (concordance rate)
Reclassified as EGPA
44
86.3%
Observational data: associations, not effects.
Further findings
Reclassification of the 7 patients not meeting 2022 EGPA criteria
- Reclassified as microscopic polyangiitis (MPA)
- 3
- Reclassified as granulomatosis with polyangiitis (GPA)
- 1
- Reclassified as unclassifiable vasculitis
- 3
Patients meeting 2022 EGPA criteria who simultaneously met criteria for another AAV subtype
- Simultaneously met MPA criteria
- 6
- Simultaneously met GPA criteria
- 1
Original publication
The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 ACR/EULAR Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. J Rheumatol. Published 15 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →